secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001104659-24-075146
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm reaches alignment with FDA on CMC for NurOwn Phase 3b ALS trial
--------------------------------------------------------------------------

- FDA alignment on Chemistry, Manufacturing, and Controls (CMC) for Phase 3b trial of NurOwn for ALS.
- Follows April 2024 Special Protocol Assessment (SPA) agreement de-risking trial design and endpoints.
- CEO Chaim Lebovits says all previously outstanding CMC questions resolved.
- Company moves forward with pivotal Phase 3b trial aiming for NurOwn approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924075146/0001104659-24-075146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924075146/tm2418335d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-075146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer